TISSIUM Raises €50M in Series D Funding to Finance its Commercial Launch and Platform Extension
BIOMARKER
1. TISSIUM, a medtech company specializing in biomorphic programmable polymers for tissue reconstruction, has raised €50 million in Series D funding from international investors.
2. The funding round comes at a crucial time for TISSIUM, coinciding with important milestones such as its first-in-human study on nerve repair product COAPTIUM Connect and ongoing regulatory activities.
3. With this financing, TISSIUM aims to commercialize its nerve and hernia repair products and expand its pipeline of products and platform.
4. The company plans to develop products in new therapeutic areas, pursue international expansion, and establish partnerships in specific verticals.
5. TISSIUM's CEO, Christophe Bancel, highlights the funding's significance in advancing tissue reconstruction and bringing innovation to patients' lives.
6. TISSIUM, based in Paris and Boston, focuses on developing and commercializing products derived from its unique biopolymer platform.
7. The company's technology is based on proprietary biosynthetic, biomorphic, and programmable polymers.
8. TISSIUM's pipeline consists of seven products across three verticals: sutureless nerve repair, hernia repair, and cardiovascular sealants.
9. Each product aims to enhance tissue reconstruction in distinct ways, and complementary delivery and activation devices are also developed for improved performance.
10. TISSIUM was co-founded in 2013 by Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women's Hospital), leveraging their world-class research and intellectual property.